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Abstract
Purpose/Objective(s): It is currently unclear whether patients with low risk breast cancer receiving adjuvant
endocrine therapy need adjuvant radiation therapy after breast conserving surgery. The data of randomized trials
are available.
Materials/Methods: In a database search 5 randomized trials including in total 3766 mostly elderly patients with
early stage breast cancer treated either with adjuvant endocrine therapy or with endocrine therapy and additional
whole breast radiation after breast conserving surgery were identified. Published hazard ratios for time to local
recurrence were the basis of our meta-analysis. Meta-analysis of the effect sizes on local recurrence was performed
using a random effects model based on parameter estimates of log hazard ratios in Cox models and their standard
errors. Furthermore, overall survival was examined.
Results: Adjuvant hormone therapy alone in mostly older patients with low risk breast cancer resulted in
significantly shorter time to local relapse compared to radiation therapy combined with hormone therapy (Hazard
Ratio: 6.8, 95% CI: 4.23–10.93, p < 0.0001) . There was no significant difference for overall survival.
Conclusion: Additional radiation therapy to hormone therapy did improve local relapse in breast cancer patients
but did not show significant impact on overall survival.
Keywords: Radiation therapy, Tamoxifen, Low risk breast cancer, Adjuvant therapy
Introduction
Randomized studies provide evidence that breast conser-
ving surgery (BCS) combined with postoperative radiation
therapy (RT) results in long-term overall survival compa-
rable to modified radical mastectomy [1–3]. Postoperative
RT leads to a significant reduction in local relapse
compared to BCS alone [2, 3]. The recent meta-analysis of
the Early Breast Cancer Trialists Collaborative Group
(EBCTCG) showed that the addition of RT after BCS is
associated with a large survival advantage in node positive
breast cancer, but only a small survival advantage in node
negative breast [1].
For most elderly women with early stage breast cancer,
the current standard treatment after BCS is adjuvant
whole-breast RT and adjuvant endocrine treatment [4–7].
The question whether RT can be safely omitted in women
with low risk breast cancer is still under debate [8–11].
Some physicians believe that combining hormonal therapy
with RT results in relevant late side effects without provi-
ding significant benefit and therefore should be abandoned.
On the other hand, published data outline RT as a highly ef-
fective therapy in reducing local recurrence rates. Therefore,
we performed a meta-analysis to investigate the importance
of additional adjuvant RT in patients with low risk breast
cancer.
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Patients and methods
The aim of this meta-analysis was to investigate the im-
pact of adjuvant radiotherapy on breast cancer patients
with low risk of recurrence. Low risk was defined as
tumor size <3 cm, N0, estrogene or progesterone recep-
tor positive disease in postmenopausal women (age
>50 years). A PubMed research with the search term
“breast and radiotherapy and (tamoxifen OR endocrine)”
restricted to “randomized trials was performed. There
was no ethics approval necessary because in this meta-
analysis we were retreiving numbers from the published
manuscripts and pooling results. Out of 218 matches 8
randomized controlled trials were identified that com-
pared sole adjuvant endocrine therapy to adjuvant endo-
crine therapy and adjuvant radiotherapy [12–14]. One
additional trial [15] was identified by screening refer-
ences of published trials and all important cancer meet-
ings like ASCO, ASTRO, ESTRO and ECCO. Three
trials were excluded, because of the inclusion of high
risk patients (node positive) and one trial could not be
included, because of inadequate reporting of the end
points local relapse and overall survival. In summary, we
were able to identify a total of five randomized prospect-
ive trials [8, 9, 11, 16, 17] that fulfilled the entry criteria.
The main characteristics of these trials are shown in
Table 1. Endpoints of the meta-analysis were local tumor
relapse and death from any cause. Because of insufficient
reporting in the majority of the identified trials, we were
unable to analyze data on disease free survival and
distant metastases free as additional endpoints.
In our meta-analysis a total of 3766 mostly elderly
women from five randomized trials with early stage
breast cancer were included to assess the potential
benefit for the addition of whole breast RT to endocrine
therapy after BCS. Analyzed end points were local recur-
rence and overall survival. Meta-analysis of the effect
sizes on time to local recurrence was performed by using
a random effects model based on parameter estimates of
log hazard ratios in Cox models and their standard
errors. Neither hazard ratios for overall survival nor
survival curves were available from most trials. However,
we were able to estimate odds ratios for death from any
cause and their confidence limits using published event
rates at 5 or 10 years, recruitment time, and median
follow up. Meta-analysis of the effect sizes on death
from any cause was performed using a random effects
model based on parameter estimates of log odds ratios
and their standard errors. Results are presented with
forest plots in which the effect size estimates of all single
studies and their combined estimate are visualized. Hori-
zontal bars indicate the amount of variation (95% confi-
dence intervals of the parameter estimates).
Results
In a Canadian study [17] the authors investigated the ef-
fect of breast irradiation plus tamoxifen on disease-free
survival and time to local relapse in women 50 years of
age or older with T1 or T2 node-negative breast cancer. A
total of 769 women with early breast cancer (tumor
Table 1 study characteristics
Fyles et al. NEJM
2004
Hughes et al.
CO 2013
Pötter et al. Int J radiation
Oncol Biol Phys 2007
Blamey et al. Eur J
Cancer 2013
Kunkler Lancet Oncol 2015
Trial design Multicenter,
randomized
Multicenter,
randomized
Multicenter, randomized Multicenter,
randomized
Multicenter, randomized
Number of patients
recruitment
769 1992–2000 636 1994–1999 869 1996–2004 204 1992–2000 1326 2003–2009
Inclusion criteria: age ≥50 years ≥70 years ≥50 yearsa ≥50 years ≥65 years
Tumor diameter <5 cm <2 cm <3 cm <2 cm <3 cm
ER/PR positiv 100% 100% 100% 100% 100%
Her-2neu unknown unknown unknown unknown Unknown, because this marker
was not routinely assessed at
the beginning of the trial
Other main inclusion
criteria
Postmenopausal
status, MO
Postmenopausal
status, MO
Postmenopausal
status, MO
Postmenopausal
status, MO
Postmenopausal status, MO
Breast surgery lumpectomy lumpectomy lumpectomy Wide local excision lumpectomy
aexeption 3 patients, minimum age 46 years
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diameter, 5 cm or less) were included in their trial and
randomly assigned to receive breast irradiation plus
tamoxifen (386 women) or tamoxifen alone (383 women).
The median follow-up time was 5.6 years. The rate of local
relapse at 5 years was 7.7% in the tamoxifen group and
0.6% in the group given tamoxifen plus irradiation (HR:
9.02; 95% CI: 3.52-23.02; p < 0.001), with corresponding 5-
year disease-free survival rates of 84 and 91% (p = 0.004).
A subgroup analysis of 611 women with T1, receptor-
positive tumors indicated a benefit from RT (5-year rates
of local relapse, 0.4% with tamoxifen plus RT and 5.9%
with tamoxifen alone; p < 0.001). In their study they dem-
onstrated a significant difference in the rate of axillary re-
lapse at 5 years (2.5% in the tamoxifen group and 0.5% in
the group given tamoxifen plus irradiation, p = 0.049), but
no significant difference in the rates of distant relapse or
overall survival (OS).
The second study which was included in our meta-
analysis was performed by the Harvard Medical
School in Boston [9]. The authors investigated a
benefit for adjuvant RT after breast-conserving sur-
gery and tamoxifen in women age >/= 70 years with
early-stage breast cancer. A total of 636 women (age
>/= 70 years) with clinical stage I (T1N0M0 accor-
ding to TNM classification) estrogen receptor (ER)-
positive breast carcinoma treated by lumpectomy were
randomly assigned to receive tamoxifen plus RT
(TamRT; 317 women) or tamoxifen alone (Tam; 319
women). Primary end points were time to locoregio-
nal recurrence, frequency of mastectomy, breast
cancer-specific survival, time to distant metastasis and
OS. Median follow-up was 12.6 years. At 10 years,
98% of patients receiving TamRT (95% CI, 96 to 99%)
compared with 90% of those receiving Tam (95% CI,
85 to 93%) were free from local and regional recurrences.
As compared with the Tam group, the TamRTgroup expe-
rienced a significantly longer time to locoregional recur-
rence (HR: 0.18; 95% CI: 0.07-0.42; p < 0.001). There were
no significant differences in time to mastectomy, time to
distant metastasis, breast cancer-specific survival, or OS
between the two groups. Ten-year OS was 67% (95% CI,
62 to 72%) and 66% (95% CI, 61 to 71%) in the TamRT
and Tam groups, respectively.
A study from Vienna and the Austrian Breast Cancer
Group [11] was designed to randomly assign 869
women (38 women were ineligible) to receive breast RT
+/− boost (n = 414) or not (n = 417) after BCS (ABCSG
Study 8A). Favorable early breast cancer was specified as
tumor size <3 cm, Grading 1 or 2, negative lymph nodes,
positive estrogen and/or progesterone receptor status,
and manageable by BCS. Breast RT was performed after
lumpectomy with two tangential opposed breast fields
with mean 50 Gy, plus boost in 71% of patients with a
mean of 10 Gy, in a median of 6 weeks. The primary
endpoint was local relapse-free survival; further end-
points were contralateral breast cancer, distant metasta-
ses, as well as disease-free and OS. The median follow-
up was 53.8 months. The mean age was 66 years. Over-
all, there were 21 local relapses, with two relapses in the
RT group (5-y rate 0.4%) vs. 19 in the no-RT group
(5.1%) (HR:10.21, (95% CI: 2.38–43.84); p = 0.002). Over-
all relapses occurred in 30 patients, with seven events in
the RT group (5-y rate 2.1%) vs. 23 events in the no-RT
group (6.1%) (HR: 3.5, p=0.002). No significant diffe-
rences were found for distant metastases and OS.
Furthermore we identified a trial from England which
was published in the European Journal of Cancer [8]. Pa-
tients with primary invasive breast cancer <2 cm diameter,
grade 1 or good prognosis special type, and node negative,
treated by wide local excision (WLE) with clear margins
were randomized into a 2 × 2 clinical trial of factorial
design with or without RT and with or without tamoxifen.
Trial entry was allowed to either comparison or both. The
actuarial breast cancer specific survival in 1135 rando-
mized patients at 10 years was 96%. Analysis by intention
to treat showed that LR after WLE was reduced in pa-
tients randomized to RT (HR 0.37, CI 0.22–0.61 p < 0.001)
and to tamoxifen (HR 0.33, CI 0.15 - 0.70 p < 0.004).
Actuarial analysis of patients entered into the four-way
randomization showed that LR after WLE alone was 1.9%
per annum (pa) versus 0.7% with RT alone and 0.8% with
tamoxifen alone. No patient randomized to both adjuvant
treatments developed LR. Analysis by treatment received
showed LR at 2.2% pa for surgery alone versus 0.8% for
either adjuvant RT or tamoxifen and 0.2% for both treat-
ments. Comparison between tamoxifen alone (n=106) and
tamoxifen+RT (n=98) resulted in a significant reduction
of local relapse in the tamoxifen+RT group (HR: 7.34, 95%
CI: 1.79-30.1; p=0.006).
Finally, the recently published results of the PRIME II
trial were included in our meta-analysis [16]. A total of
1326 women aged 65 years or older with early breast
cancer judged low-risk (i.e., hormone receptor-positive,
axillary node-negative, T1-T2 up to 3 cm at the longest
dimension, and clear margins; grade 3 tumor histology
or lymphovascular invasion, but not both, were permit-
ted), who underwent BCS and were receiving adjuvant
endocrine treatment, were recruited into a phase 3
randomized controlled trial at 76 centers in four
countries. Eligible patients were randomly assigned to
either whole-breast RT (40–50 Gy in 15–25 fractions)
or no RT by computer-generated permuted block
randomization, stratified by center, with a block size
of four. The primary endpoint was ipsilateral breast
tumor recurrence. Women who had undergone BCS
and who were receiving adjuvant endocrine treatment
were randomly assigned to receive whole-breast
irradiation and 668 were allocated to no further
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treatment. After median follow-up of 5 years (IQR
3.84–6.05), ipsilateral breast tumor recurrence was
1.3% (95% CI 0.2–2.3; n = 5) in women assigned to
whole-breast RT and 4.1% (95% CI 2.4–5.7; n = 26) in
those assigned no RT (p = 0.0002). Compared with women
allocated to whole-breast RT, the univariate hazard ratio
for ipsilateral breast tumor recurrence in women assigned
to no RT was 5.19 (95% CI 1.99–13.52; p = 0.001). No dif-
ferences in regional recurrence, distant metastases,
contralateral breast cancers, or new breast cancers were
noted between groups. Five-year OS was 93.9% (95% CI
91.8–96.0) in both groups (p = 0.34); 89 women died; eight
of 49 patients allocated to no RT and four of 40 assigned
to RT died from breast cancer.
Tamoxifen without RT results in an increase of
local relapse (Figs. 1 and 2). After 10 to 20 years
there is a significantly higher risk of up to 20% that
patients develop a local relapse. Patients receiving RT
and endocrine therapy have a very low local relapse
rate of less than 5%. We found that treatment with
tamoxifen alone in older patients and low risk breast
cancer did result in shorter time to local relapse com-
pared to a combination of both therapeutic strategies
(HR: 6.8, 95% CI: 4.23–10.93, p < 0.0001).
For death from any cause, neither in the individual
trials nor in the meta-analysis statistically significant
differences between treatments were observed (Odds
ratio 1.09, 95% CI 0.81–1.48, p = 0.57) (Fig. 3). At 5-
and 10-year overall survival were within the expected
range of an age matched US general population [18].
Using the 95% CI of the odds ratio of the meta-
analysis, neither a survival benefit for the addition of
radiotherapy to endocrine therapy of 3% at 5 years
and 7% at 10 years nor a survival disadvantage of 1%
at 5 years and 2% at 10 years can be excluded.
Side effects
Side effects were reported from the Canadian trial by Fyles
et al [17]. They report that adverse events according to
CTC-criteria did not differ significantly between tamoxi-
fen plus RT and tamoxifen alone (n = 39 in the Tamoxifen
and RT group and n = 30 in the Tamoxifen alone group, p
= 0.33). In a subgroup of this trial Rayan et al [19]. investi-
gated the impact of RT on breast pain and quality of life
and found no adverse influence of irradiation [20].
In a subgroup analysis of the PRIME II trial Williams
et al [21] reported that omission of radiation therapy did
not improve quality of life after 5 years in a very detailed
EORTC QLC-C30 and EORTC QLC-B23 questionnaire.
Only insomnia was significantly more frequent in the
patient group with Tamoxifen alone. Some differences
were apparent with subscales of the questionnaires. Two
patients in the Tamoxifen plus RT group developed
fibrosis °III, whereas few patients (number of patients
not published) developed fibrosis °II in the Tamoxifen
alone group. Retraction/atrophy °II occurred similar in
both groups (number of patients not published), whereas
°III developed in 1 patient in the Tamoxifen plus RT
group.
In, summary the authors conclude that RT is well
tolerated and does not impair quality of life.
A detailed overview of the side effects and quality of
life questionnaire of all trials is shown in Table 2.
Discussion
There is a large debate on the role of RT in elderly
women with low risk breast cancer. The results of
large randomized trials are summarized in this meta-
analysis. Of note, this meta-analysis is limited by the
absence of individual patient data, which were not
available.
Fig 1 Hazard ratios for local relapse Results are presented with forest plots in which the estimates of the hazard ratios of all single studies and
their combined estimate are visualized. Horizontal bars indicate the amount of variation (95% confidence intervals of the parameter estimates)
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Radiation in addition to endocrine treatment following
BCS in low risk breast cancer patients (<3 cm diameter,
hormone receptor positive, N0, postmenopausal) substan-
tially reduces the hazard to develop a local recurrence by
a factor of 6.8 (CI 4.4–11.9; p < 0,001) (Fig. 2). However,
additional radiation did not translate into a significant
improvement in OS in this group [8–11, 16, 17, 22, 23],
although the available data do not exclude a survival
advantage of 3% at 5 years and up to 7% at 10 years. The
absolute risk for local recurrence with endocrine therapy
alone is quite low at 5 years (<5%), but increases conti-
nuously to about 10% at 10 years with no recognisable
plateau thereafter in the only trial with long term
follow to 15 years [10]. The rate of secondary mastec-
tomies has been reported from two trials indicating a
4.4 – 6.0 fold risk [Kunkler et al.: 1.8% (12/668) vs.
0.3% (2/658), p > 0.05.; Hughes et al.: 8.5% (27/319)
vs. 2% (6/315), p < 0.05], if radiotherapy is omitted. It
remains unclear how patients should be advised in
clinical practise in view of the large risk reduction by
radiotherapy in terms of local relapse, but no proven
advantage in terms of overall survival. Obviously,
omission of radiotherapy is quite safe in low risk
breast cancer patients with limited life expectancy
below 5 years. As most patients will present with sub-
stantially longer life expectancies individual counseling
about the risks and benefits of radiotherapy is
strongly recommended. Detailed data on toxicities are
not available from the trials included in this meta-
analysis. However, acute and long term toxicity of ad-
juvant radiotherapy using hypofractionated radiother-
apy schedules like 15× 2.66 Gy in 3 weeks is quite
limited, if modern radiation techniques are used [24].
Therefore, radiotherapy is a reasonable option espe-
cially for patients with low risk breast cancer having
life expectancies greater than 10 years.
Fig. 2 Time to local recurrence. Blue letters: treatment arm with Tamoxifen (Tam) only without RT. Red letters: TAM + RT
Fig. 3 Odds ratio for death to any course. Results are presented with Odds ratio with confidence intervals in forest plots. Horizontal bars indicate
the amount of variation (95% confidence intervals of the parameter estimates)
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Further subgroup analyses could help to identify
patients who may not substantially benefit form radio-
therapy. In this regard, it is important to mention one of
the limitations of the present meta-analysis as we had no
access to individual patients data and were consequently
unable to look for such subgroups. Another weakness of
the available data and consequently the presented meta-
analysis is the unknown Her2-status in all studies. Liu et
al. [20] retrospectivly analysed a number of molecular
markers (HER2, CK5/6, EGFR, Ki-67) from a part of the
patients in the Canadian trial [17]. They found that
patients with luminal A and B like breast cancer had a
small benefit from radiotherapy in addition to endocrine
treatment (luminal A: HR = 0.4, p = 0.11; luminal B HR
= 0.51, p = 0.18), whereas patients with Her2-positive
and triple negative disease had a larger advantage from
radiotherapy in terms of locoregional relapse (HER2-
positive/“triple negative”: HR = 0.13, p = 0.0015). Accord-
ing to these observations omission of radiotherapy
would be safe in patients above 70 years with small node
negative, luminal A breast cancer. However, independent
prospective confirmatory data are required.
Regarding side effects the authors of the mentioned
trials conclude that radiation therapy is well tolerated
without excess toxicity. Side effects as well as the quality
of life (QLC-C30 and QLC-B23) did not differ signifi-
cantly between the irradiated groups and the patient
groups receiving Tamoxifen alone. Of note, the trials
performed by Blamey, Kunkler and Pötter did not
publish information on side effects.
Another question is whether endocrine treatment is
needed after BCS in patients above 70 years with small
node negative breast cancer, if adjuvant radiotherapy is
administered. According to the results of two rando-
mized trials [8, 14] sole adjuvant endocrine therapy and
sole adjuvant radiotherapy are equivalent regarding all
important oncological endpoints. Endocrine therapy is
frequently associated withfatigue symptoms and possible
severe side effects, as thromboembolic events and endo-
metrial cancer related to tamoxifen as well as osteo-
porosis and arthralgia related to aromatase inhibitors. In
view of the at least 5 years lasting endocrine the typical
side effects of a three weeks hypofractionated adjuvant
radiotherapy like faint erythema and minor edema
appear relatively moderated and of short duration.
Another discussion is whether partial breast radiother-
apy could represent an alternative treatment option for
low risk breast cancer patients and result in comparable
local control rates as whole breast radiotherapy. In a
recently published meta-analysis (Marta et al. 2015) of
eight randomized trials (n = 8653) comparing whole
breast radiotherapy with partial breast radiotherapy a
significantly higher rate of in-breast recurrences was re-
ported for partial breast radiotherapy (HR = 4.54, 95%
CI: 1.78–11.61, p = 0.002). Interestingly, the hazard in
favour for whole breast radiation vs. partial breast
radiation is in the same range as in the meta-analysis re-
ported here (HR=6.8) for the comparison of whole
breast radiotherapy to no radiotherapy (endocrine treat-
ment in all patients in both comparisons), raising the
question, whether partial breast radiotherapy is any bet-
ter than no radiotherapy at all. In the absence of direct
randomized comparisons and in view of the different
characteristics of patients included in these two meta-
analyses, the question cannot conclusively be answered.
Conclusions
In summary adjuvant RT in addition to standard endo-
crine therapy in low risk breast cancer patients was not
associated with a significantly improved overall survival,
but reduced the hazard of local recurrence substantially
by a factor of 6.8 corresponding to an absolute decrease
in local recurrence of 3–5% at 5 years and 9–14%
10 years. Individual counselling is of high clinical rele-
vance in this situation. However in view of the relatively
low toxicity of modern radiotherapy, adjuvant radiothe-
rapy should be advised in patients with life expectancies
larger than 5–10 years.
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